Advanced Drug-resistant Cell Models for Cancer Therapeutic Resistance Studies
Abstract
Despite an increase in the number of novel anti-cancer drugs, the persistence of drug resistance remains a major challenge in cancer research. Cell-based models are critical tools for understanding the mechanisms of drug resistance and developing novel therapeutics. This workshop highlighted how state-of-the-art ATCC drug-resistant cancer cell models created by CRISPR gene-editing technology can facilitate the discovery of new types of therapeutics that overcomes drug resistance. In addition, cell models for combination therapy studies were discussed in this session.
Presenter
Fang Tian, PhD
Director, Biological Content, ATCC
Dr. Fang Tian, Director of Biological Content for ATCC, has extensive experience in cell biology and molecular biology. She oversees human, animal cell lines and hybridomas, and product development in the Cell Biology General Collection at ATCC. Dr. Tian was a research fellow in Massachusetts General Hospital, Harvard Medical School. She conducted postdoctoral research at the Hillman Cancer Institute of UPMC.
Resources for cancer research
Isogenic cells
Clinically relevant cell models are critical for studies of molecular and cellular mechanisms of tumors, as well as for drug screening for cancer. With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for elucidating molecular pathways of cancer progression.
Explore isogenic cells
THP-1 reporter cells
ATCC offers luciferase reporters containing the response element of immunologically important transcription factors into the THP-1 cell line. These advanced models provide a robust and highly sensitive means to measure immune activation through in vitro bioluminescence.
Order THP-1 reporter cell lines
EMT reporter cells
Epithelial-mesenchymal transition (EMT) and its reverse, MET, can play critical roles in promoting metastasis and invasion and contribute to drug resistance in carcinoma. ATCC used CRISPR gene editing to develop new reporter lines designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal.
Enhance your research
Next-generation cancer models
ATCC is offering scientists a wide variety of next-generation patient-derived in vitro cancer models, including organoids, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These advanced models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.
Discover how
Luciferase-labeled cell lines
ATCC is bridging the gap between the in vitro and the in vivo by offering luciferase-labeled cell lines for biological mechanism studies and drug development; these advanced models provide a relatively simple, robust, and highly sensitive means to measure biological processes and to assess drug efficacy in live animal models through bioluminescence imaging.
Get started
Cancer panels
ATCC offers a wide variety of cancer cell lines for use in research related to cancer genetics, early detection methods, and effective treatment of disease. Panels of these cell lines offer researchers the value of several lines for comprehensive studies. Explore our panels by tissue type, genetic mutation, or molecular signature.
Order cancer panels
